Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1575, 2007-01, pp. : 7-8
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :
Access to resources
Recommend
Nilotinib better than imatinib, dasatinib for CML in Colombia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 645, 2012-01 ,pp. :
Imatinib still cost effective for CML
Inpharma, Vol. 1, Iss. 1639, 2008-01 ,pp. :
Imatinib effective in paediatric CML and ALL
Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. :
Dasatinib: a once-daily option for imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. :